ArticleDermatology research and practice2012
Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases.
Article in Dermatology research and practice, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 148 citations in OpenAlex.
- Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Trial
- [Cutaneous clear cell sarcoma].Pathologie (Heidelberg, Germany) · 2026Review
- Cytological Features of Clear Cell Sarcoma in Exfoliative and Effusion Cytology Specimen-A Case Report and Literature Review.Diagnostic cytopathology · 2026Review
- A thigh-stakes diagnosis: Recurrent acral melanoma presenting as a rapidly enlarging mass.JAAD case reports · 2026Article
- Clear Cell Sarcoma Incidence and Survival: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis.Cureus · 2025Article
- Surgically Treated Clear Cell Sarcomas - What Influences Outcomes?Indian journal of surgical oncology · 2025Article
- Article
- Clear Cell Sarcoma (CCS) of the Soft Tissue: An Update Narrative Review with Emphasis on the Utility of PRAME in Differential Diagnosis.Journal of clinical medicine · 2025Review
- Prognostic factors in clear cell sarcoma: an analysis of soft tissue sarcoma in 43 cases.Journal of cancer research and clinical oncology · 2024Article
- Metastatic clear cell sarcoma of the pancreas: An overview.World journal of clinical cases · 2024Article
- Medical imaging for the diagnosis, recurrence and metastasis evaluation of clear cell sarcoma.World journal of clinical cases · 2024Article
- Spitz melanoma with MAP3K8::ABLIM1 rearrangement: a case report with review of the literature.Diagnostic pathology · 2024Review
- Shedding light on pancreatic metastasis of clear cell sarcoma: An exceptional journey.World journal of clinical cases · 2024Article
- Essential role of postoperative follow-up in the management of clear cell sarcoma.World journal of clinical cases · 2024Article
- Navigating diagnostic challenges-distinguishing malignant melanoma and clear cell sarcoma of soft tissues: a case report and review of the literature.Journal of medical case reports · 2024Review
- Metastatic clear cell sarcoma of the pancreas: A rare case report.World journal of clinical cases · 2024Article
- Lymphadenectomy in the treatment of sarcomas - indications and technique.Oncology reviews · 2024Review
- Rare Primary Malignant Melanoma of the Breast Presenting as a Solitary Breast Mass in a 43-Year-Old Male.Cureus · 2023Article
- Molecular testing of soft tissue tumors.Diagnostic cytopathology · 2023Review
- Primary clear cell sarcoma of soft tissue in the posterior cervical spine invading the medulla oblongata: A case report.World journal of clinical cases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell sarcomas are aggressive, rare soft tissue tumors and their classification among melanoma or sarcoma is still undetermined due to their clinical, pathologic, and molecular properties found in both types of tumors. This is a retrospective study of 52 patients with CCS seen between April 1979 and April 2005 in two institutions. The EWS-ATF-1 fusion transcript was studied in 31 patients and an activating mutation of the BRAF or NRAS gene was researched in 22 patients. 30 men and 22 women, with a mean age of 33 were studied. Forty-three tumors (82.69%) were located in the extremities, specially the foot (19 tumors). Median initial tumor size was 4.8 cm (1 to 15 cm). Necrosis involving more than 50% of the tumor cells was found in 14 cases (26.92%). High mitotic rate (>10) was found in 25 cases (48.07%). The EWS/ATF-1 translocation was found in 28 (53.84%) of 31 patients studied, and mutation of BRAF or NRAS was found in only 2 of 22 patients analyzed cases (3.84%). Among the tumor-associated parameters, only tumor size (>4 cm) emerged as a significant prognostic factor. Forty-nine patients had a localized disease at diagnosis (94.23%) and underwent surgical resection immediately (90%) or after neoadjuvant chemotherapy (CT) (10%). Various CT regimens were used in 37 patients (71.15%) with no significant efficacy. The 5- and 10-year OS rates were 59% and 41%, respectively. Tumor size was the only emerging prognosis factor in our series. Complete surgical resection remains the optimal treatment for this aggressive chemoresistant tumor.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.